Clinical Trial Update: High Septal Pacing for Cardiac Resynchronization Therapy

View source ↗

Summary

Boston Scientific's clinical trial evaluating high-septal pacing for cardiac resynchronization therapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Left Bundle Branch Block

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Heart Failure, Left Bundle Branch Block | Status: TERMINATED